Updates are available Correction dated 2023-09-15
Click to view Correction: https://doi.org/10.1186/s13075-023-03158-9
-
Authors
Schett, Georg http://orcid.org/0000-0001-8740-9615
Chen, Warner
Gao, Sheng
Chakravarty, Soumya D. http://orcid.org/0000-0001-7957-838X
Shawi, May http://orcid.org/0000-0001-6005-3938
Lavie, Frederic http://orcid.org/0000-0002-5213-257X
Zimmermann, Miriam
Sharaf, Mohamed
Coates, Laura C. http://orcid.org/0000-0002-4756-663X
Siebert, Stefan http://orcid.org/0000-0002-1802-7311
- License Information
-
More Information
Article History
Received: 17 April 2023
Accepted: 26 July 2023
First Online: 16 August 2023
Change Date: 15 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13075-023-03158-9
Declarations
:
: The governing ethical bodies for each of the 84 participating sites approved the COSMOS trial protocol.
: Not applicable.
: GS has received speaker fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, Novartis, and UCB.WC and SG are employees of Janssen Research & Development, LLC, and own stock or stock options in Johnson & Johnson, of which Janssen Research & Development, LLC is a wholly owned subsidiary.SDC is an employee of Janssen Scientific Affairs, LLC, and owns stock or stock options in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly owned subsidiary.MShawi is an employee of Immunology Global Medical Affairs, Janssen Pharmaceutical Companies, a wholly owned subsidiary of Johnson & Johnson, and owns stocks in Johnson & Johnson.FL is an employee of Immunology Global Medical Affairs, Janssen Pharmaceutical Companies, a wholly owned subsidiary of Johnson & Johnson, and owns stock in Johnson & Johnson.MZ is an employee of Janssen Medical Affairs, LLC, and owns stock or stock options in Johnson & Johnson, of which Janssen Medical Affairs, LLC, is a wholly owned subsidiary.MSharaf is an employee of Johnson & Johnson MEA and owns stock or stock options in Johnson & Johnson.LCC has received consultant fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, MoonLake, Novartis, Pfizer, and UCB; grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and speaker fees from AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Medac, Novartis, Pfizer, and UCB.SS has received institutional research grants from AbbVie, Amgen (previously Celgene), Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, and UCB; and speaker fees from AbbVie, Amgen, Biogen, Eli Lilly, GlaxoSmithKline, Janssen, and UCB.
